Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947395 · ClinicalTrials.gov registry record
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
A clinical trial of Pancreatic Cancer and Cancer of the Pancreas, sponsored by Immunovia.
- Completed
- Registry status
- 386
- Enrollment target
- 6
- Study locations
NCT06947395 is a study of Pancreatic Cancer and Cancer of the Pancreas that has completed, run by Immunovia. The registered enrollment target is 386 participants, roughly in line with the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target. The trial reports 6 study locations across 6 states.
The verdict
NCT06947395, a study of Pancreatic Cancer and Cancer of the Pancreas, has completed, sponsored by Immunovia.
- COMPLETED
- Registry status
- 386 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PancreaSure
Study Locations (6)
Arizona
- HonorHealth Clinical Research Institute - Scottsdale
New York
- New York University Langone Health - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Tennessee
- Regional One Health - Memphis
Texas
- UT Southwestern Medical Center - Dallas
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2025-04-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06947395
The ClinicalTrials.gov registry entry for NCT06947395 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target. The listed sponsor is Immunovia, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PancreaSure is the first listed.
NCT06947395 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06947395 about?
NCT06947395 is a clinical study titled "Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)". This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of dis...
What is the current status of trial NCT06947395?
This trial is currently completed. The enrollment target is 386 participants. The study started on 2025-02-11. Estimated completion is 2025-04-07.
What conditions does trial NCT06947395 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Cancer of the Pancreas, Pancreas Neoplasms, Pancreatic Carcinoma Stage I, Pancreatic Carcinoma Stage II.
What interventions are being tested in trial NCT06947395?
The interventions under investigation include: PancreaSure (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06947395?
This trial is sponsored by Immunovia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947395 being conducted?
This trial has 6 study locations across Arizona, New York, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.